Phendimetrazine
- Generic Name
- Phendimetrazine
- Brand Names
- Fendique
- Drug Type
- Small Molecule
- Chemical Formula
- C12H17NO
- CAS Number
- 634-03-7
- Unique Ingredient Identifier
- AB2794W8KV
- Background
Phendimetrazine is a weight loss medication. Phendimetrazine is chemically related to amphetamines and is a Schedule III drug under the Convention on Psychotropic Substances and in the US since 1970.
- Indication
Used in the management of exogenous obesity as a short term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction.
- Associated Conditions
- Exogenous Obesity
- Associated Therapies
- -
Earnings call: Elite Pharmaceuticals posts robust Q2 growth, eyes future
Elite Pharmaceuticals Inc. reported a 33% revenue increase to $18.9 million in Q2 FY2025, with year-to-date revenues up 63% to $37.7 million. Operating income doubled to $3.5 million, and cash flow turned positive at $4.6 million. The company launched new products and anticipates significant ANDA approvals, projecting record revenues of $56 million for FY2024. Despite increased liabilities, the company maintains a strong cash position and robust pipeline, expressing confidence in future growth.
Phentermine and other psychotropic drugs prescribed as 'diet pills'
Psychotropic drugs like phentermine are being prescribed as diet pills, with over 1,079.29 million such drugs prescribed to 8.35 million patients from 2020 to June 2023. Dietamin and Phendira tablets, containing phentermine and phendimetrazine, accounted for 86.3% of patients and 92% of prescriptions. Lorcaserin-based drugs, despite FDA warnings, were prescribed to 7,109 patients from 2020-2022.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath